Results 61 to 70 of about 7,241 (205)

Impact of FCGR2A and FCGR3A Gene Variants on the Response to Rituximab in Patients With Glomerular Diseases

Pharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT Rituximab is an anti‐CD20 monoclonal antibody used in autoimmune diseases, including glomerular diseases. The FCGR2A (rs1801274) and FCGR3A (rs396991) variants have been suggested to affect rituximab efficacy; this study evaluates their impact on rituximab efficacy in glomerular diseases.
María Larrosa‐García, Irene Agraz Pamplona, Susana Rojo Tolosa, Alberto Jiménez Morales, María Teresa Sanz Martínez, Mónica Martínez Gallo, Roger Colobran, Helena Genestal Vicente, Nerea Moreno Pena, Roxana Paola Bury Macías, José Bruno Montoro Ronsano   +10 more
wiley   +1 more source

Profile of Primary Membranous Nephropathy among Membranous Nephropathy Patients Based on PLA2 Receptor Staining in Biopsy [PDF]

, 2021
INTRODUCTION: Membranous nephropathy is one of the common cause of nephrotic syndrome in adults. MN usually presents with nephrotic syndrome or heavy proteinuria, while renal function is often normal or near normal. Disease progression is variable, with
Mohamed Aaseem Arshad, V S
core  

Advances in Erectile Dysfunction Management: What Does Work

Trends in Urology &Men's Health, Volume 17, Issue 3, June 2026.
ABSTRACT Erectile dysfunction (ED) is a prevalent and multifactorial disorder that substantially affects quality of life. Pathophysiology includes vascular, neurogenic, drug‐induced, and psychogenic causes, and frequently coexists with cardiometabolic disease.
Jolie Shen, Daye Park, Jasper Bash, Juan Andino   +3 more
wiley   +1 more source

Rituximab for Idiopathic Membranous Nephropathy [PDF]

Clinical Journal of the American Society of Nephrology, 2006
Rituximab effectively reduces proteinuria in patients with idiopathic membranous nephropathy (IMN), but response to treatment may vary from patient to patient. The association between baseline clinical, laboratory, and histology covariates and proteinuria reduction was evaluated retrospectively by multiple linear regression analysis at 3 mo after ...
Piero, Ruggenenti, Carlos, Chiurchiu, Mauro, Abbate, Annalisa, Perna, Paolo, Cravedi, Mario, Bontempelli, Giuseppe, Remuzzi   +6 more
openaire   +2 more sources

Computational Modeling Meets 3D Bioprinting: Emerging Synergies in Cardiovascular Disease Modeling

Advanced Healthcare Materials, Volume 15, Issue 17, 8 May 2026.
Emerging advances in three‐dimensional bioprinting and computational modeling are reshaping cardiovascular (CV) research by enabling more realistic, patient‐specific tissue platforms. This review surveys cutting‐edge approaches that merge biomimetic CV constructs with computational simulations to overcome the limitations of traditional models, improve ...
Tanmay Mukherjee, Mehdi Salar Amoli, Sarah Rezapourdamanab, Lama Rita El Shammas, Martin L. Tomov, Emilio A. Mendiola, Vahid Serpooshan, Reza Avazmohammadi   +7 more
wiley   +1 more source

Recurrence of Idiopathic Membranous Nephropathy in a Renal Allograft

, 1975
Idiopathic membranous nephropathy, also termed "membranous glomerulonephritis," "extramembranous glomerulonephritis," "Ellis type 2 nephritis," and "epimembranous nephropathy,"1,2 is a well-recognized cause of nephrotic syndrome.
Crosson, John T, Andersen, Robert C, Anderson, W. Robert, Raij, Leopoldo, Wathen, Ronald L   +4 more
core   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Development and validation of a discrimination model between primary PLA2R-negative membranous nephropathy and minimal change disease confirmed by renal biopsy

Scientific Reports, 2021
Membranous nephropathy (MN) and minimal change disease (MCD) are two common causes leading to nephrotic syndrome (NS). They have similar clinical features but different treatment strategies and prognoses.
Feng Wu, Yiding Zhang, Wen Cui, Yijun Dong, Yingyang Geng, Changhao Liu, Zemeng Li, Yandong Xie, Xiaojing Cai, Jin Shang, Jing Xiao, Zhanzheng Zhao   +11 more
doaj   +1 more source

Adventitial Niches, Complement and Inflammation in Pulmonary Vascular Disease: Current Status and Future Directions

Comprehensive Physiology, Volume 16, Issue 2, April 2026.
Local complement production by pulmonary artery adventitial fibroblasts, activated intracellularly by CFD and CFB and extracellularly by GZMK+ CD8 T cells, and its secretion in soluble form and within EVs promotes macrophage and T cell chemotaxis and activation.
Hui Zhang, Ram Raj Prasad, Sushil Kumar, Min Li, Dallas Jones, Cheng‐Jun Hu, Claudia Mickael, Yen‐Rei Yu, Rubin M. Tuder, Kurt R. Stenmark   +9 more
wiley   +1 more source

Treatment of idiopathic membranous nephropathy in adults: KDIGO 2012, cyclophosphamide and cyclosporine A are out, rituximab is the new normal [PDF]

, 2019
The 2012 Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guidelines for glomerulonephritis shed light on the complex world of glomerulonephritis therapy.
Carriazo, Sol, Rojas-Rivera, Jorge Enrique, Ortiz Arduán, Alberto   +2 more
core   +1 more source